Kornimate/medical-research-clean huggingface dataset:
use of bepreve (bepotastine besilate ophthalmic solution) 1.5% for allergic conjunctivitis and contact lenses

Conditions: Allergic Conjunctivitis

Summary: the purpose of this study is to assess if bepreve (bepotastine besilate ophthalmic solution) 1.5% will have an effect on contact lens wear in patients with contact lens intolerance due to allergic conjunctivitis.


Eligibility criteria:
inclusion criteria: * history of allergic conjunctivitis * history of contact lens intolerance * between the ages of 18 and over inclusive. * males or females * patient is in generally good \& stable overall health. * patient likely to comply with study guidelines \& study visits. informed consent signed. * are willing/able to return for all required study visits. * are willing/able to follow instructions from the study investigator and his/her staff. * if a woman capable of becoming pregnant, agree to have urine pregnancy testing performed at screening (must be negative) and agree to use a medically acceptable form of birth control throughout the study duration and for at least one week prior to and after completion of the study. women considered capable of becoming pregnant include all females who have experienced menarche and who have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). * have signed informed consent approved by institutional review board or independent ethics committee. exclusion criteria: * corneal refractive surgery within 6 months of this study. * current use of restasis * intra-ocular surgery within 6 months or ocular laser surgery within 6 months. * pregnant or lactating women. * ocular pathology (includes glaucoma and cataract), which could impact results and/or place patient at risk. * systemic or injected corticosteroids (including oral, parenteral, intravenous, rectal) 30 days; * nasal or inhaled or ocular corticosteroids 14 days; * nasal or inhaled ipratropium bromide (or atropine), inhaled nedocromil, or nasal, inhaled, or ophthalmic sodium cromolyn 14 days; * agents with antihistaminic/anticholinergic activity (e.g. antidepressants, antipsychotics) 14 days; * leukotriene pathway modifiers (accolate, singulair, zyflo) 10 days; * ocular anti-allergy medications including lodoxamide (alomide), olopatadine (patanol/pataday), emedastine difumarate (emadine), epinastine (elestat), levocabastine (livostin) 7 days; * non-steroidal anti-inflammatory ophthalmics including bromfenac (xibrom), ketorolac (acular/acuvail), nepafenac (nevanac), flurbiprofen (ocufen), suprofen (profenal), diclofenac (voltaren) 7 days; * otc ophthalmic decongestant, antihistamine, or decongestant/antihistamine combinations 3 days; * other anticholinergic agents 3 days * immunotherapy injection 1 day.

Keywords: allergic conjunctivitis
fetal abdominal subcutaneous tissue thickness in prediction of fetal weight in term pregnant women

Conditions: Ultrasound; Fetal Weight

Summary: fetal abdominal subcutaneous tissue thickness (fastt) can be easily measured during the routine ultrasound examination of pregnant women. numerous reports have shown fastt measurement to be a good way of evaluating subcutaneous fat tissue. however, to the best of our knowledge, no studies have investigated the association of fastt with abnormal fetal growth in nondiabetic. for this reason, in this study we evaluated whether fastt can predict birth weight or diagnose lga and/or lbw infants in the third trimester.

the fetal weight assessment by ultrasound is essential in obstetric practice to determine the labor mode, time, and management. it is an important to detect fetal growth abnormalities such as small for gestational age (sga), fetal growth restriction (fgr) and large for gestational age (lga) fetuses; thus, it could help in decreasing the perinatal morbidity and mortality rates \[1\]. many methods have been introduced to estimate the weight in utero, and many studies have evaluated their effectiveness to detect the most accurate method \[2\]. abnormal fetal growth can be diagnosed by ultrasound. conventional ultrasonic measurements, such as estimated fetal weight (efw) and abdominal circumference (ac) can distinguish lga/macrosomia or lbw infants. many studies have demonstrated that expected fetal weight (efw) by the traditional techniques is not a reliable indicator of growth abnormalities; consequently several other sono graphic measurements have been proposed \[3\]. ultrasound has its limitations despite the use of more than 50 different formulae to estimate fetal weight as their performance is poor at the extremes of fetal weight. there has been emerging interest in studying fetal soft tissue measurements to improve the detection of growth abnormalities \[4\]. fetal abdominal subcutaneous tissue thickness (fastt) can be easily measured during the routine ultrasound examination of pregnant women. numerous reports have shown fastt measurement to be a good way of evaluating subcutaneous fat tissue \[5\].furthermore, some researchers have investigated links between fastt and diabetes \[6\]. however, to the best of our knowledge, no studies have investigated the association of fastt with abnormal fetal growth in nondiabetic. for this reason, in this study we evaluated whether fastt can predict birth weight or diagnose lga and/or lbw infants in the third trimester.

Eligibility criteria:
inclusion criteria: 1. singleton pregnancy. 2. gestational age between 37-42 weeks. 3. accepting to be included in the study exclusion criteria: 1. pre-gestational diabetes and gestational diabetes. 2. other medical disorder as hypertensive disorder during pregnancy, cardiac diseases. 3. congenital fetal malformation affecting birth weight or affecting clavicle.
otx-ded for the short-term treatment of the symptoms of dry eye disease (ded)

Conditions: Dry Eye Syndromes; Eye Diseases

Summary: to assess the efficacy and safety of otx-ded for the short-term treatment of the symptoms of ded

randomized, double-masked, study to evaluate the efficacy and safety of otx-ded (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of the symptoms of dry eye disease (ded). the subjects will be followed for approximately two months.

Eligibility criteria:
inclusion criteria: * vas eye dryness severity score ≥ 35 and ≤ 90 at screening. * investigator assessment of bulbar conjunctival hyperemia grade ≥ 2 (cclru; 0 - 4 scale). * unanesthetized schirmer of \> 0 and ≤ 10 mm. * must not have used artificial tears during the screening period. * iop in both eyes ≥ 5 mmhg and ≤21 mmhg. exclusion criteria: * have worn contact lenses in the 4 weeks prior to the screening visit and/or are unwilling to discontinue use of contact lenses throughout the study period. * have a history of glaucoma or ocular hypertension or have a history of intraocular pressure (iop) \ 24 mmhg.
percutaneous electrical nerve stimulation (pens) of the auricle for post operative pain solution(pops) - cardiac surgery

Conditions: Post Operative Pain; Midline Sternotomy Incision

Summary: percutaneous electrical nerve stimulation (pens) of the auricle for acute pain management post cardiac surgery

a well formulated analgesic protocol is fundamental to fast tracking post cardiac surgery. traditional analgesic methods have their own set of drawbacks unique to cardiac surgery. opioids have well established side effects like nausea, vomiting, respiratory depression, urinary retention. regional anesthetic techniques in anti coagulated patients may result in potentially catastrophic neurological, bleeding and thromboembolic sequelae. non steroidal anti inflammatory drugs (nsaids) have been associated with increased cerebrovascular events, renal dysfunction, sternal wound infections. these make alternative therapies, including non pharmacological modalities, attractive options for optimal analgesic therapy during the post operative period. alternative methods like topical application of cox -2 inhibitors, intravenous magnesium, transcutaneous electrical nerve stimulation (tens) have been tried with varied results in cardiac surgery. a somatotopic relationship has been described between the auricle and the other anatomical regions of the body. when specific points are accurately identified along the meridians of the ear and stimulated electrically, analgesic effects are known to occur. percutaneous electrical nerve stimulation (pens) of the auricle and its efficacy in management of post midline sternotomy pain has not been evaluated previously. primary relief v 2.0 is a device which provides continuous pens aimed at non pharmacological post operative pain management.

Eligibility criteria:
inclusion criteria: * cardiac surgery patient with midline sternotomy incision exclusion criteria: 1. thoracotomy incisions 2. patients with pacemakers, 3. post operative cognitive dysfunction 4. anticipated ventilation \> 24 hrs 5. pre operative opioid therapy 6. ear infections 7. skin lesions / allergy to adhesive materials 8. re-exploration for any reason

Keywords: cardiac surgery pain reduction post operative pain pens neurostimulation
palliative care population management project for integrated care management program for high-risk patients

Conditions: Failure to Thrive

Summary: the hypothesis of the serious illness care program (sicp) is that adherence to the serious illness conversation guide (sicg) portion, the sigc, will enhance patient understanding and allow control over their own decisions, relieve burdens of decision-making on family members, and help patients achieve a state of peace as they approach the end of life.

the aim of the serious illness care program (sicp) is to provide clinicians with an evidence-based structure for eliciting and documenting vital information about preferences for patient driven care of their serious illness. it is designed to help open the door for patients, families, and clinicians to talk and reflect on end-of-life issues in an ongoing way. the hypothesis of the serious illness care program is that adherence to the conversation guide portion, the sigc, will enhance patient understanding and allow control over their own decisions, relieve burdens of decision-making on family members, and help patients achieve a state of peace as they approach the end of life. for this protocol specifically, the investigators are testing a pilot intervention of a quality improvement project; the investigators plan to train clinicians and assess the feasibility and impact of the serious illness care program, which includes patient identification, clinician training, "triggering" of clinicians to conduct the sicg conversation, and documentation, in the icmp at the brigham and women's hospital.

Eligibility criteria:
clinician inclusion criteria: 1. brigham and women's hospital or newton wellesley primary care clinician at one of the following practices: the phyllis jen center for primary care, faulkner community physicians, brigham and women's physician group, brigham \& women's primary care associates of brookline, brigham circle medical associates, faulkner 2. care for patients enrolled in brigham and women's hospital integrated care management program (icmp) clinician exclusion criteria: 1. resident in training 2. non-english speaking clinic (e.g. spanish clinic) patient inclusion criteria: 1. over 18 years of age 2. english speaker 3. patient at brigham and women's hospital or newton wellesley primary care clinician at one of the following practices: the phyllis jen center for primary care, faulkner community physicians, brigham and women's physician group, brigham \& women's primary care associates of brookline, brigham circle medical associates, faulkner 4. enrolled in brigham and women's hospital integrated care management program patient exclusion criteria: 1. patient at dana-farber cancer institute

Keywords: care management end of life advanced care planning palliative care
disturbance of the intestinal microbiota by temocillin vs cefotaxime in treatment of febrile urinary tract infections

Conditions: Urinary Tract Infections

Summary: this study will evaluate the ecological impact on the intestinal microbiota and compare the safety and efficacy of temocillin compared to cefotaxime, in empiric treatment of febrile uti. half of participants will receive temocillin and the other half will receive cefotaxime.

temocillin is a narrow spectrum antibiotic with activity against gram negative bacteria inclusive many esbl producing bacteria. temocillin is approved and marketed in a few european countries since the 1980´s but not in sweden. the aim of the study is to find an ecological favorable alternative to cephalosporins in the treatment of this common indication. the hypothesis is that treatment with temocillin causes less disturbances on the intestinal microbiota while at least comparable efficacy. the study will be performed as an open prospective multicentre study with two parallel groups comparing 2 g temocillin three times daily with 1-2 g cefotaxim three times daily for 7-10 days in male and female adult patients with febrile urinary tract infection.

Eligibility criteria:
inclusion criteria: * males and females ≥ 18 years of age with suspected or confirmed febrile uti, fulfilling at least one of the following signs and symptoms: * flank pain or suprapubic pain, tenderness over the kidney on physical examination, urinary symptoms such as dysuria, urinary frequency or urinary urgency * fever ≥ 38.0°c (highest temperature recorded at home or at the hospital) * positive urinalysis tests (u-nitrit and/or u-lpk) * have a pre-treatment baseline urinary culture obtained * require iv antibacterial treatment of the presumed infection * fertile women: agree to practice highly effective anti-contraceptive methods from study-start to toc * signed informed consent exclusion criteria: * have a documented history of hypersensitivity or allergic reaction to any beta-lactam * pregnant or nursing women * receipt of any prior potentially therapeutic antibacterial agent within 1 month before randomisation and sampling for urine and faecal cultures. exceptions will prior treatment with pivmecillinam or nitrofurantoin. * known chronic renal insufficiency (creatinine clearance \< 10 ml/min at screening as estimated by cockcroft-gault), or receiving intermittent haemodialysis or peritoneal dialysis * known colonization with esbl * any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the subject or the quality of study data.
safety and efficacy of spirinolactone plus hydroflumethiazide in the treatment of filipino patients with hypertension

Conditions: Hypertension

Summary: aldazide 25 mg od will be given to filipino hypertensive patients, and there will be 2 follow-up visits on week 4 and week 8 to monitor for safety and efficacy as primary and secondary outcomes, respectively.

prospective, non-interventional non-probability sampling

Eligibility criteria:
inclusion criteria: * patients \>/= 18 years old with stage 1 or 2 hypertension not controlled by monotherapy or by a combination of anti-hypertensives without any diuretic yet. exclusion criteria: * pregnant or lactating women, with hypersensitivity to aldazide, patients with resistant hypertension not controlled by a combination therapy with a diuretic in their regimen

Keywords: spirinolactone hydroflumethiazide hypertension filipinos diabetes mellitus proteinuria
role of minoxidil in alopecia areata transepidermal drug delivery of minoxidil via either fractional carbon dioxide laser or microneedling versus its topical nanoparticles preparation for treatment of alopecia areata

Conditions: Alopecia Areata

Summary: * compare the clinical efficacy, and safety of transepidermal drug delivery of fractional co2 laser versus microneedling followed by minoxidil 5% application for the treatment of alopecia areata. * evaluate the efficacy, and safety of minoxidil nanoparticles as a topical treatment of alopecia areata.

alopecia areata (aa) is the most common cause of non-scarring alopecia. (hordinsky, 2013). although many patients improve spontaneously or respond to standard therapy, in patients with more severe and refractory disease, management can be quite challenging (messenger et al., 2012 and kranseler and sidbury, 2017). corticosteroids either topical or intralesional are the most popular medications used to treat this condition. other therapies such as topical minoxidil (mxd), anthralin, immunotherapy, systemic corticosteroids are also commonly used with variable success (shumez et al., 2015). patients treated with mxd 5% have significant hair growth than placebo. minoxidil was more effective for patchy alopecia than other types of aa such as ophiasis and alopecia totalis. it was ineffective in alopecia universalis (el-taib et al., 2017). in contrast, the incidence of adverse events associated with 10% mxd treatment was higher than with 5% mxd treatment. therefore, new approaches are required to achieve both expected efficacy and safety (oaku et al., 2022). the combination of non-ablative laser and topical mxd can be a good alternative therapy for aa patients, including alopecia totalis and alopecia universalis, without systemic and local side effects (wang et al., 2019) according to follicle deposition and diffusion experiments, minoxidil nanoemulsions penetrated hair follicles 26 times more efficiently than standard treatment (cardoso and barradas, 2020). to the best our knowledge no previous research studied the effect of nanominoxidil solution in treatment of aa except in animal or compare transepidermal drug delivery versus topical nanominoxidil.

Eligibility criteria:
inclusion criteria: * the study will include patients with alopecia areata exclusion criteria: * children below 18 years , pregnant and lactating women . patients with chronic hepatic, hematological disorders or immunocompromised patients. patient recieved any treatment for alopecia areata in the last 3 months before the study. patients with extensive types (alopecia totalis, universalis and surface area \>50%).
point of care ultrasound evaluation in the post-anesthesia unit

Conditions: Hypotension; Hypoxemia; Altered Mental Status; Urine Output Low; Chest Pain

Summary: the purpose of this observational research study is to examine how point-of care ultrasound affects the workup and management of perioperative complications for specific clinical scenarios of low blood pressure (hypotension), low blood oxygen (hypoxemia), in the post- anesthesia care unit (pacu).


Eligibility criteria:
inclusion criteria: * patients in the post-anesthesia care unit with the following events * mean arterial blood pressure \<60 mmhg or \<20% of pre-operative baseline mean arterial blood pressure,) hypoxemia (pulse oximetry saturation \<95% or pao2 \<80), altered mental status, decreased urine output, chest pain/ekg changes, or to confirm endotracheal lube placement. exclusion criteria: * patients who are not able to have a point of care ultrasound examination in the post anesthesia recovery area.
study on the performance of a machine learning algorithm recognizing and triaging large vessel occlusions using non-contrast ct scans

Conditions: Stroke, Ischemic; Stroke Hemorrhagic; Stroke, Acute; Brain Ischemia

Summary: the goal of this prospective observational study is to assess the effectiveness and performance of methinks ai stroke imaging software platform in acute code stroke patients, and as a comparator to study sites utilizing existing ai imaging stroke platforms. the main question\[s\] it aims to answer is: • performance of and outcomes associated with the use of the methinks ai stroke imaging medical device in real-world clinical practice.

this is a prospective observational medical device clinical trial that aims to assess the diagnostic performance of methinks investigational device on detecting lvo and ich on plain ncct and cta, in consecutive acute code stroke activations at the emergency department. demographic, clinical and imaging variables will be collected from stroke onset through day 7 or discharge, whichever is earlier. methinks results will be collected exclusively for research purposes and no clinical decisions will be made based on the output. diagnostic performance of ncct-lvo methinks output will be assessed using dsa and/or cta as ground truth. presence of ich will be assessed using an independent neuroradiologist final reading. the clinical impact on workflow will be retrospectively estimated based on the reduction of time to decision in both transfer patients and the ones directly arriving to the emergency department (ed) informed consent forms (icf) will be waived, as approved by the irb.

Eligibility criteria:
inclusion criteria: * subjects with acute neurological symptoms suggestive of stroke, ischemic or hemorrhagic ("code stroke"), regardless of presence or absence of ﬁnal stroke diagnosis. * subjects aged 22 years or older. * ncct performed for code stroke screening. * if the patient does not have a hemorrhage, a cta (head and neck, performed for code stroke screening) should also be performed. * ncct and cta have been processed by methinks ai software. exclusion criteria: ● subject imaging does not meet image acquisition and dicom tag requirements
efficacy of periodontal treatment on glycaemic control in diabetic patients

Conditions: Diabetes

Summary: this study will assess the efficacy of periodontal treatment in diabetic patient. patients will be randomized in the periodontal group or in the control group. the control group will received a periodontal treatment after the study.


Eligibility criteria:
inclusion criteria: * patient suffering from a periodontitis * patient with : 7,0% \< hemoglobin a1c \< 9,5% exclusion criteria: * if an hospitalization is planned within the next 4 months * patient suffering from chronic infectious pathology (hiv, hepatitis c virus, hepatitis b virus, mononucleosis) * renal insufficiency * contra indication for amoxicilline or clindamycin * antithrombotic treatment * liver disease

Keywords: diabetic patients periodontal treatment glycaemic control